The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Abbott (NYSE:ABT) said it closed the buyout of OptiMedica Corp. it announced in July, paying $250 million up front with another $150 million on the table if development, regulatory and sales milestones are met.
The buyout expands the Chicago-area healthcare giant’s Abbott Medical Optics ophthalmology unit by adding femtosecond laser-assisted cataract surgery to its portfolio.
Abbott (NYSE:ABT) said it agreed to acquire a pair of companies in the peripheral stent and ophthalmic space for a total of up to $710 million.
The Chicago-ares medical device company said it inked a deal worth $310 million for Webster, Texas-based IDEV Technologies and its Supera Veritas stent for treating peripheral artery disease.
Intarcia Therapeutics said it’s reeled in financing worth a total of $210 million to further its drug-device combination treatment for Type II diabetes.
The Hayward, Calif.-based company, which is moving its headquarters to Boston, said the cash will also help facilitate the move.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Updated: July 18, 2012 11:30 a.m.
OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn’t shy about extolling his company’s potential.
MASSDEVICE ON CALL — A team of U.K. researchers is calling for a ban on metal-on-metal hip implants, citing studies that demonstrate that they fail more often than other artificial hips, especially when used in women.
U-Systems won a date with the FDA to review its pre-market application for the first ultrasound device indicated for breast cancer screening.
The somo.v Abus device, which is set to undergo agency review on April 11, 2012, is already FDA-cleared for diagnostic use as an adjunct to a mammogram.
Updated Dec. 23, 2011, to correct that the HeartNavigator is inserted through a small incision in the leg, not in the chest.
Philips’ HeartNavigator aortic valve replacement system uses x-ray imaging to guide the valve to the heart.Philips Healthcare (NYSE:PHG) landed FDA clearance for its HeartNavigator heart valve replacement system.
Medical City Dallas Hospital became the first U.S. hospital to use the system, which was launched in Europe in the first quarter of this year.
St. Jude Medical Inc. (NYSE:STJ) announced a med-tech first with a European CE Mark approval for its Genesis implanted neurostimulation device for patients with chronic migraines.
Genesis, which is the first device of its kind to win regulatory approval in any market, provides peripheral nerve stimulation to the occipital nerves to manage migraines. Small electrical leads are placed under the skin and connected to a device which produces pulses of stimulation.
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
